Accessibility Menu
BioRegenx logo

BioRegenx(OTC) BRGX

Market Cap$7.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-87%
5 Year-88%
1 Year-9%
1 Month+7%
$0.01
+0.00%
+0.00Today
BioRegenx last closing stock price
MetricPriceDate
Last closeUSD 0.012026-08-28
BioRegenx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+33.33%USD 0.012026-08-19
1 month+6.67%USD 0.012026-07-29
3 month-2.21%USD 0.012026-05-28
Year to date-37.98%USD 0.012025-12-31
1 year-8.55%USD 0.012025-08-27
3 year-84%USD 0.052023-08-25
5 year-87.69%USD 0.072021-08-27
Since inception-86.95%USD 0.062024-03-12

BioRegenx Financials at a Glance

Market Cap

$7.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.77M

Net Income (TTM)

-$1.30M

EPS (TTM)

-$0.00

P/E Ratio

-5.71

Dividend

$0.00

Beta (Volatility)

-0.21 (Low)

Price

$0.01

Volume

90,000

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.03

Estimated Earnings Date

N/A

BRGX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioRegenx

BioRegenx creates health products and digital tools for medical professionals and consumers. Its main offerings help monitor blood vessel health and support healthy aging. These products aim to make health tracking and wellness more accessible for clinics and individuals.

Products and Services

  • Nutritional Products: Supplements for blood vessel health and aging, 87.4% of 2025 revenue, sold to clinics and consumers.
  • Medical Testing Equipment: GlycoCheck system for microvascular health assessment, 11.2% of 2025 revenue, used by researchers and doctors.
  • Wellness Devices: Muscle stimulation and electromagnetic field devices, 1.4% of 2025 revenue, for therapy and recovery.
  • Digital Health Platforms: Mobile apps for health monitoring and DNA analysis, targeting both professionals and end users.
  • Content Management Platforms: Online tools for managing and sharing health-related content, used by practitioners and organizations.

Growth and Expansion

  • Acquired DocSun Biomedical Holdings in January 2024 to add AI diagnostic technology.
  • TruScan.Ai and VitalWellness health apps are in development, with TruScan.Ai anticipated for release in the third quarter of 2027.
  • Entered online marketplaces like Amazon and Walmart in 2025 to reach more customers.
  • Signed a technical services agreement with a major software company for DocSun AI Engine distribution in China, Hong Kong, and Macao.
  • Secured a sublicense and purchase agreement for GlycoCheck technology in 2025.

What Makes BioRegenx Stand Out

The company combines AI-powered diagnostics, patented supplements, and digital health apps in one portfolio. Its recurring revenue model relies on subscriptions and repeat supplement sales. BioRegenx uses a multi-channel approach, selling directly to professionals and through online platforms.

Five Things You Need to Know

  • Gross sales were $1.86 million in 2025, down 28% from 2024.
  • Nutritional products made up 87.4% of 2025 gross sales.
  • Gross margin rose to 81.1% in 2025, up from 70.9% in 2024.
  • Net loss improved to $1.54 million in 2025, down 93% from 2024.

Bottom Line

BioRegenx has shifted from direct sales to digital and online channels, focusing on integrated health solutions. The company’s evolution shows adaptability but faces ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

6

CEO

William Resides

Website

bioregenx.com

Headquarters

Chattanooga, TN 37421, US

BRGX Financials

Key Financial Metrics (TTM)

Gross Margin

81.90%

Operating Margin

-21.30%

Net Income Margin

-73.80%

Return on Equity

31.83%

Return on Capital

N/A

Return on Assets

-386.56%

Earnings Yield

-17.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

971.58M

Volume

90.00K

Avg. Volume

8.58K

Financials (TTM)

Gross Profit

$1.45M

Operating Income

-$376.14K

EBITDA

-$337.88K

Operating Cash Flow

$27.91K

Capital Expenditure

-$9.06K

Free Cash Flow

$18.85K

Cash & ST Invst.

$45.81K

Total Debt

$2.17M

BioRegenx Performance Analysis

BioRegenx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 42,159-78.8%
20232023-12-31USD 3,411,4157991.8%
20242024-12-31USD 2,340,106-31.4%
20252025-12-31USD 1,854,513-20.8%
BioRegenx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-13.4%
Q32025-09-3013.9%
Q42025-12-31-24.0%
Q12026-03-3110.5%
BioRegenx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00-25.0%
20232023-12-31USD -0.011766.7%
20242024-12-31USD -0.02337.5%
20252025-12-31USD -0.00-93.5%
BioRegenx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3033.3%
Q32025-09-3050.0%
Q42025-12-31-900.0%
Q12026-03-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$426.18K

-17.3%

Gross Profit

$348.29K

-14.2%

Gross Margin

81.72%

N/A

Market Cap

$7.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.30M

N/A

Employees

6

N/A

Net Income

-$26.42K

+90.1%

EBITDA

-$36.82K

+80.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$45.81K

-45.2%

Total Debt

$2.17M

+0.0%

Accounts Receivable

$18.38K

+64.8%

Inventory

$92.81K

-33.9%

Long Term Debt

$182.56K

-29.0%

Short Term Debt

$1.98M

+3.9%

Return on Assets

-3.87%

N/A

Return on Invested Capital

10.30%

N/A

Free Cash Flow

$26.63K

-29.4%

Operating Cash Flow

$26.63K

-29.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CREVFCarbon Revolution Limited
$0.00+0.00%
KVILKidville, Inc.
$0.00+0.00%
DTCSolo Brands, Inc.
$19.55-3.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About BRGX

What is the current price of BioRegenx?

BioRegenx is trading at $0.01 per share.

What is the 52-week range for BioRegenx?

Over the past 52 weeks, BioRegenx has traded between $0.01 and $0.03.

How much debt does BioRegenx have?

As of the most recent reporting period, BioRegenx reported total debt of $2.17M.

How much cash does BioRegenx have on hand?

BioRegenx reported $45.81K in cash and cash equivalents in its most recent financial results.

What is BioRegenx’s dividend yield?

BioRegenx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services